Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 322 W 57Th St. #33B NEW YORK NY 10019 |
Tel: | N/A |
Website: | https://shop.mydario.com |
IR: | See website |
Key People | ||
Richard Allan Anderson President | Erez Raphael Chief Executive Officer, Director | Zvi Ben-David Chief Financial Officer, Treasurer, Secretary | Tomer Ben-Kiki Chief Operating Officer |
Business Overview |
DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management. |
Financial Overview |
For the fiscal year ended 31 December 2023, DarioHealth Corp revenues decreased 26% to $20.4M. Net loss applicable to common stockholders decreased 1% to $63.5M. Revenues reflect Services decrease of 27% to $13.1M, Hardware and consumable products decrease of 26% to $7.3M. Lower net loss reflects Marketing and Pre-Production Cost decrease of 29% to $17.3M (expense), Interest Exp-Net of Capitalized Interest decrease from $1.9M (expense) to $0K. |
Employees: | 276 as of Mar 22, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $25.61M as of Dec 31, 2023 |
Annual revenue (TTM): | $20.35M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.08M as of Dec 31, 2023 |
Net annual income (TTM): | -$63.51M as of Dec 31, 2023 |
Free cash flow (TTM): | -$30.96M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,442,532 as of Mar 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |